Search Results - "Jiulien Maria de Pourcq, Sven"

TP53 VAF as an Easier Prognostic Indicator in Myelodysplastic Neoplasms in Comparison With Tp53 Allelic Status by Rigodanza, Luca, Andreossi, Gloria, Consagra, Angela, Sanna, Alessandro, Mattiuz, Giorgio, Jiulien Maria de Pourcq, Sven, Gabriele Raddi, Marco, Santini, Valeria

Get full text

MDS-679 TP53 VAF as an Easier Prognostic Indicator in Myelodysplastic Neoplasms in Comparison With Tp53 Allelic Status by Rigodanza, Luca, Andreossi, Gloria, Consagra, Angela, Sanna, Alessandro, Mattiuz, Giorgio, de Pourcq, Sven Jiulien Maria, Gabriele Raddi, Marco, Santini, Valeria

“…Biallelic TP53 inactivation negatively affects overall survival (OS) and leukemia-free survival (LFS) of patients with myelodysplastic syndromes (MDS), whereas…”
Get full text

MDS-462 Response to Erythropoiesis-Stimulating Agent Therapy in IPSS-R Lower Risk Myelodysplastic Syndrome Patients Restratified According to IPSS-M by Rigodanza, Luca, Consagra, Angela, Alessandro, Sanna, Cassari, Margherita, Tofacchi, Elena, de Pourcq, Sven Jiulien Maria, Mattiuz, Giorgio, Amato, Cristina, Raddi, Marco Gabriele, Santini, Valeria

“…Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemic low-risk myelodysplastic syndrome (MDS) patients. Response to these agents is…”
Get full text

POSTER: MDS-462 Response to Erythropoiesis-Stimulating Agent Therapy in IPSS-R Lower Risk Myelodysplastic Syndrome Patients Restratified According to IPSS-M by Rigodanza, Luca, Consagra, Angela, Alessandro, Sanna, Cassari, Margherita, Tofacchi, Elena, de Pourcq, Sven Jiulien Maria, Mattiuz, Giorgio, Amato, Cristina, Raddi, Marco Gabriele, Santini, Valeria

Get full text